Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world evaluation of interactions between anticancer small molecule inhibitors and direct oral anticoagulants in solid tumors
NL-OMON52100Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Dec 2021
- Countries
- 1
01
Overview
Open-label trial in Nonhematologic neoplasms and thromboembolism (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: DOAC trough concentration before and after concomitant SMI use and DOAC peak concentration before and after concomitant SMI use. Started Dec 2021; status: completed.
02
Conditions
Nonhematologic neoplasmsthromboembolism
Beyond the preview
Go deeper on NL-OMON52100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52100.